Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYG-LIV0001 in End-Stage Liver Disease
NCT04496479Phase 2Recruiting
- Sponsor
- LyGenesis
- Start
- Mar 2022
- Primary completion
- Aug 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LYG-LIV-001 in liver disease, sponsored by LyGenesis. Primary endpoints: Dosage Selection at Week 12, Safety of Engraftment of Hepatocytes in to Lymph Nodes at Week 12 and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
LYG-LIV-001
03
Conditions
liver disease
Beyond the preview
Go deeper on NCT04496479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04496479.